Sub-population analysis of human cancer vaccine cells - Ultra scale-down characterization of response to shear

Biotechnology and Bioengineering

Volumn 106, Issue 4, 2010, Pages 584-597

  McCoy, Ryan ^a   Ward, Stephen ^b   Hoare, Mike ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cell integrity; Cell phenotype; Human cells; Hydrodynamic shear; Sub population; Ultra scale down

Indexed keywords

CELL INTEGRITY; CELL PHENOTYPE; HUMAN CELLS; HYDRODYNAMIC SHEAR; ULTRA SCALE-DOWN;

CELL CULTURE; CELL MEMBRANES; FLUID DYNAMICS; GROWTH KINETICS; MAINTENANCE; SHEAR DEFORMATION; VACCINES;

HYDRODYNAMICS;

CANCER VACCINE; CD147 ANTIGEN; CD59 ANTIGEN; CD9 ANTIGEN;

ARTICLE; BIOPROCESS; CELL GROWTH; CELL LINE; CELL SUBPOPULATION; CELL SURFACE; HUMAN; HUMAN CELL; HYDRODYNAMICS; PHENOTYPE; SHEAR STRESS; STAINING; VALIDATION PROCESS; WHOLE CELL;

ANTIGENS, SURFACE; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL LINE; CELL MEMBRANE; HUMANS; MASS SCREENING; STRESS, MECHANICAL; STRESS, PHYSIOLOGICAL;

EID: 77954248704     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22716     Document Type: Article

References (53)

1. Al-Rubeai M, Singh RP, Goldman MH, Emery AN. 1995. Death mechanisms of animal cells in conditions of intensive agitation. Biotechnol Bioeng 45(6):463-472.
2. Anon. 2005. Quality Risk Management. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Guideline Q9: 1-19.
3. Anon. 2008a. Pharmaceutical Development. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Guideline Q8(R1): 1-24.
4. Anon. 2008b. Pharmaceutical Quality System. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Guideline Q10: 1-17.
5. Augenstein DC, Sinskey AJ, Wang DIC. 1971. Effect of shear on the death of two strains of mammalian tissue cells. Biotechnol Bioeng 13(3):409-418.
6. Boychyn M, Yim SSS, Ayazi Shamlou P, Bulmer M, More J, Hoare M. 2001. Characterization of flow intensity in continuous centrifuges for the development of laboratory mimics. Chem Eng Sci 56:4759-4770.
7. Butler PJ, Norwich G, Weinbaum S, Chien S. 2001. Shear stress induces a time and position dependent increase in endothelial cell membrane fluidity. Am J Physiol Cell Physiol 27:671-678.
8. Cochran JR, Aivazian D, Cameron TO, Stern LJ. 2001a. Receptor clustering and transmembrane signalling in T-cells. Trends Biochem Sci 26(5):304-310.
9. Cochran JR, Cameron TO, Stone JD, Lubetsky JB, Stern LJ. 2001b. Receptor proximity, not intermolecular orientation, is critical for triggering T-cell activation. J Biol Chem 276(30):28068-28074.
10. Diepolder HM, Gruener NH, Gerlach JT, Jung M-C, Wierenga EA, Pape GR. 2001. Different levels of T-cell receptor triggering induce distinct functions in hepatitis B and hepatitis C virus-specific human CD4+ T-cell clones. J Virol 75(17):7803-7810.
11. Eaton JD, Perry MJA, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS. 2002. Allogeneic whole cell vaccine: A phase I/II study in men with hormone refractory prostate cancer. Br J Urol Int 89:19-26.
12. EMEA/CHMP/BWP/271475/2006. 2006. Committee for medicinal products for human use (CHMP) guideline on potency testing of cell based immunotherapy medicinal products far the treatment of cancer.
13. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. 2003. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109-123.
14. Fletcher CM, Harrison RA, Lachmann PJ, Neuhaus D. 1994. Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure 2(3):185-199. (Pubitemid 124002589)
15. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. 2005. EMMPRIN/ CD147, an MMP modulator in cancer, development and tissue repair. Biochemie 87:361-368.
16. Harris JE, Ryan L, Hoover HC, Jr., Stuart RK, Oken MM, Benson AB III, Mansour E, Haller DG, Manola J, Hanna MG, Jr. 2000. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18(1):148-157.
17. Hoover H, Jr., Brandhorst J, Peters L, Surdyke M, Takeshita Y, Madariaga J, Muenz L, Hanna M, Jr. 1993. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11(3):390-399.
18. Hsueh EC, Nathanson L, Foshag LJ, Essner R, Stern SL, Morton DL. 1999. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 85(10):2160-2169.
19. Hutchinson N, Bingham N, Murrell N, Farid S, Hoare M. 2006. Shear stress analysis of mammalian cell suspension for prediction of industrial centrifugation and its verification. Biotechnol Bioeng 95(3):483-493.
20. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C. 2004. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal cell carcinoma after radical nephrectomy: Phase III, randomised control trial. Lancet 363:594-599.
21. Keane JT, Ryan D, Gray PP. 2003. Effect of shear stress on expression of a recombinant protein by chinese hamster ovary cells. Biotechnol Bioeng 81(2):211-220.
22. Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG. 1996. Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine. Melanoma Res 6(4):299-306.
23. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, et al. 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13(5):1552-1561.
24. Liu AY. 2000. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60:3429-3434. (Pubitemid 30482160)
25. Lustig HJ, Bianco C. 1976. Antibody-mediated cell cytotoxicity in a defined system: Regulation by antigen, antibody, and complement. J Immunol 116(1):253-260.
26. Ma N, Koelling K, Chalmers JJ. 2002. Fabrication and use of a transient contractional flow device to quantify the sensitivity of mammalian and insect cells to hydrodynamic forces. Biotechnol Bioeng 80(4):428-437.
27. Ma G, Aucamp J, Hoare M, Zhou Y. 2009. Mimic of a large-scale diafiltration process by using an ultra scale-down rotating disc filter. Biotechnol Prog DOI 10.1002/btpr.327.
28. Mardikar SH, Niranjan K. 2000. Observations on the shear damage to different animal cells in a concentric cylinder viscometer. Biotechnol Bioeng 68(6):697-704.
29. McCoy R, Ward S, Hoare M. 2009. Ultra scale-down studies of the effect of shear on cell quality; processing of a human cell line for vaccine cancer therapy. Biotechnol Prog 25(5):1448-1458.
30. McQueen A, Bailey JE. 1989. Influence of serum level, cell line, flow type and viscosity on flow induced lysis of suspended mammalian cells. Biotechnol Lett 11:531-536.
31. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. 2005. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11(12):4469-4478.
32. Miyake M, Nakano K, Ieki Y, Adachi M, Hueng C-L, Itoi S, Koh T, Taki T. 1995. Motility related protein 1 (MRP-1/CD9) expression: Inverse correlation with metastases in breast cancer. Cancer Res 55:4127-4131.
33. Miyake M, Adachi M, Huang C, Higashiyama M, Kodama K, Taki T. 1999. A novel molecular staging protocol for non small cell lung cancer. Oncogene 18:2397-2404.
34. Mollet M, Ma N, Zhao Y, Brodkey R, Taticek R, Chalmers J. 2004. Bioprocess equipment: Characterization of energy dissipitation rate and its potential to damage cells. Biotechnol Prog 20:1437-1448.
35. Mollet M, Godoy-Silva R, Berdugo C, Chalmers JJ. 2007. Acute hydrodynamic forces and apoptosis: A complex question. Biotechnol Bioeng 98(4):772-788.
36. Mollet M, Godoy-Silva R, Berdugo C, Chalmers JJ. 2008. Computer simulations of the energy dissipation rate in a fluorescence-activated cell sorter: Implications to cells. Biotechnol Bioeng 100(2):260-272.
37. Moreira JL, Alves PM. 1995. Hydrodynamic effects on BHK cells grown as suspended natural aggregates. Biotechnol Bioeng 46(4):351-360.
38. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff RM, Irie RF. 1992. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216(4):463-482.
39. Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, et al. 2002. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236(4):438-448.
40. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. 2005. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11(6):2327-2336.
41. Petricciani J, Egan W, Vicari G, Furesz J, Schild G. 2007. Potency assays for therapeutic live whole cell cancer vaccines. Biologicals 35(2):107-113.
42. Repmann R, Goldschmidt AJ, Richter A. 2003. Adjuvant therapy of renal cell carcinoma patients with an autologous tumour cell lysate vaccine: A 5-year follow-up analysis. Anticancer Res 23(2a):969-974. (Pubitemid 36750904)
43. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M. 1999. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen presenting cells and cytokines. J Immunol 163:130-136.
44. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. 2000. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191(3): 423-433.
45. Sho M, Adachi M, Taki T, Hashida H, Konishi T, Huang C, Ikeda N, Nakajima H, Hisanaga M, Nakano H, et al. 1998. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 79:509-516.
46. Traub O, Berk BC. 1998. Laminar shear stress; mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc 18:677-685. (Pubitemid 28267645)
47. Uchida S, Shimada Y, Watanbe G, Gang Li Z, Hong T, Miyake M, Imamura M. 1999. Motility-related protein (MRP-1/CD9) and KAI/CD82 expression is inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 79:1168-1173.
48. Vilella R, Benitez D, Mila J, Vilalta A, Rull R, Cuellar F, Conill C, Vidal-Sicart S, Costa J, Yachi E, et al. 2003. Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. Int J Cancer 106:626-631.
49. Ward S, Copier J, Dalgleish A. 2008. Technical challenges facing therapeutic cancer vaccines. Curr Opin Drug Discov Dev 11(2):168-177. (Pubitemid 351281056)
50. Yamamoto K, Takahashi T, Asahara T, Ohura N, Sokabe T, Kamiya A, Ando J. 2003. Proliferation, differentiation and tube formation by endothelial progenitor cells in response to shear stress. J Appl Physiol 95:2081-2088.
51. Zhang H, Yu J, Chen S, Morgan BP, Abagyan R, Tomlinson S. 1999. Identification of the individual residues that determine human CD59 species selective activity. J Biol Chem 274(16):10969-10974.
52. Zhang H, Kong S, Booth A, Boushaba R, Levy S, Hoare M. 2007. Prediction of shear damage of plasmid DNA in pump and centrifuge operations using an ultra scale-down device. Biotechnol Prog 23:858-865.
53. Zoro BJH, Owen S, Drake RAL, Hoare M. 2008 The impact of a process stress on suspended anchorage-dependent mammalian cells as an indicator of likely challenges for regenerative medicines. Biotechnol. Bioeng 99:468-474.